|Bid||0.00 x 1400|
|Ask||0.00 x 1200|
|Day's Range||90.61 - 91.04|
|52 Week Range||79.39 - 93.12|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.72|
|Expense Ratio (net)||0.08%|
On November 16, Merck’s (MRK) stock price closed at $76.06, which represents ~1.63% growth from its close of $74.84 on November 15. Merck’s stock price grew from $56.79 when the market opened on January 2 to $76.06 when the market closed on November 16, which representing ~34% year-to-date growth. On November 16, Merck hit its 52-week high of $76.25.
When the stock market gets rough, investors often flee to dividend stocks, which explains why iShares Core High Dividend is now in IBD's ETF Leaders screen of top ETFs.
On October 25, Merck & Co. (MRK) announced a dividend of $0.55 per share for its outstanding common stock in the fourth quarter of 2018. That’s a ~15% increase from its dividend of $0.48 per share in the fourth quarter of 2017.
The consensus target price for 3M stock has fallen since its earnings release. The current analyst consensus indicates a target price of $205.94, compared to $213.60 before its third-quarter earnings release.
Johnson & Johnson’s (JNJ) Vision Care segment generated revenues of $1.13 billion in the third quarter compared to $1.09 billion in the third quarter of 2017, reflecting ~3.8% YoY (year-over-year) growth.
In this part, we’ll compare Pfizer’s (PFE) valuation with its peers including Merck (MRK), Johnson & Johnson (JNJ), Eli Lilly (LLY), and Bristol-Myers Squibb (BMY).
Analysts expect Merck (MRK) to report GAAP net income of $2.23 billion and GAAP EPS of $0.83 in the third quarter of 2018. In Q2 2018, the company’s GAAP net income fell YoY (year-over-year) from $1.9 billion to $1.7 billion, and its GAAP EPS fell YoY from $0.71 to $0.63. Merck’s non-GAAP net income grew ~3% YoY in Q2 2018, to $2.9 billion from $2.8 billion, and its non-GAAP EPS grew ~5% YoY from $1.01 to $1.06.
In June, Pfizer (PFE) announced a dividend of $0.34 for the third quarter on the company’s common stock. Pfizer paid a cash dividend of $0.34 on September 4 to its shareholders of record on August 3. Pfizer delivered a dividend yield of 3.11% in the third quarter.
The universe of exchange-traded funds (ETFs) is awash in low-fee products and that space is growing as issuers use discounted fees to lure investors.
President Donald Trump enacted a tax reform plan that allowed companies to repatriate billions of dollars in overseas revenue back home, driving increased demand for dividend stock ETF strategies that ...
In 1Q18, Merck’s revenue grew 6% YoY (year-over-year) to $10.0 billion from $9.4 billion, and its EPS (earning per share) rose to $1.05 from $0.88. In this part, we’ll look at how Merck’s valuation multiples compare.
As discussed earlier, Johnson & Johnson (JNJ) reported revenue growth of 12.6% in its 1Q18 revenues to $20.0 billion.
Johnson & Johnson (JNJ) reported revenues of $20.2 billion during 4Q17—11.5% growth compared to 4Q16. Wall Street analysts expect Johnson & Johnson to generate earnings per share of $2.00 on revenues of $19.4 billion in 1Q18—9.2% revenue growth compared to $17.8 billion in 1Q17. The revenue growth is expected to be driven by increased sales across all three business segments.
When it comes to investing in dividend funds, there are a few trade-offs to be aware of. Of course, everyone is looking for low-cost dividend funds, and yet low-cost dividend funds usually mean passively managed exchange-traded funds or mutual funds. Expenses are going to rise as you move into higher-yielding securities that require more active management.